Biomarker may predict who'll benefit from targeted therapy for HER2-negative breast cancer
A multicenter team led by Case Western Reserve has demonstrated that brief exposure to a targeted therapy can tell doctors which HER2-negative patients will respond—and which should switch to another kind of treatment.
Sep 17, 2015
0
5